Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation

Fig. 3

Sorafenib suppressed the EMT of HCC cells after insufficient RFA. Sorafenib was used to treat HCC cells, the morphological changes of HepG2 and SMMC7721 after insufficient RFA were displayed (a) and western blot was used to determine the expression of MMP-2, MMP-9, E-cadherin, N-cadherin, vimentin, snail (b), p-Akt, Akt, p-ERK1/2 and ERK1/2 (c)

Back to article page